Frauenheilkunde up2date, Table of Contents Frauenheilkunde up2date 2021; 15(03): 205-215DOI: 10.1055/a-1468-1052 SOP / Arbeitsablauf SARS-CoV-2/COVID-19 – aktualisierte Empfehlungen zu Diagnostik und Therapie Authors Berthold Bein Martin Bachmann Susanne Huggett Petra Wegermann Recommend Article Abstract Buy Article(opens in new window) All articles of this category(opens in new window) Dieser Übersichtsartikel ist als praktische Handreichung für alle gedacht, die COVID-19-Patienten behandeln, und fasst das derzeit verfügbare Wissen zu Diagnostik und Therapie zusammen. Zusätzlich werden auch neue und experimentelle Therapien bewertet. Full Text References Literatur 1 Johns Hopkins Coronavirus Resource Center. Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. Im Internet: http://bit.ly/3cb8Mbk 2 Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 2020; 109: 102433 3 Andersen KG, Rambaut A, Lipkin WI. et al. The proximal origin of SARS-CoV-2. Nat Med 2020; 26 (04) 450-452 4 Adhikari SP, Meng S, Wu Y-J. et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty 2020; 9: 29 5 Wang CJ, Ng CY, Brook RH. Response to COVID-19 in Taiwan. JAMA 2020; 323 (14) 1341-1342 6 Robert Koch-Institut – RKI. Virus und Epidemiologie (Stand: 6.1.2021). Im Internet: http://bit.ly/3t0yLbl 7 Robert Koch-Institut – RKI. Übersicht und Empfehlungen zu neuen SARS-CoV-2-Virusvarianten. Im Internet: bit.ly/3rbs8RZ; Stand: 23.01.2021 8 WHO. SARS-CoV-2 Variant – United Kingdom of Great Britain and Northern Ireland. Im Internet: http://bit.ly/2M4zurw 9 Makoni M. South Africa responds to new SARS-CoV-2 variant. Lancet 2021; 397(10271): 267 10 Wu JT, Leung K, Bushman M. et al. Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. Nat Med 2020; 26: 506-510 11 Cruz A, Zeichner S. COVID-19 in children: initial characterization of the pediatric disease. Pediatrics 2020; 145 (06) e20200834 12 Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. JAMA 2020; 323 (13) 1239-1242 13 Center of Disease Control. Healthcare Professionals: frequently asked questions and answers. CDC. Im Internet: http://bit.ly/39fODPx;%20Stand:%2023.01.2021 14 Bao L, Deng W, Gao H. et al. Reinfection could not occur in SARS-CoV-2 infected rhesus macaques. bioRxiv. Cold Spring Harbor Laboratory; 2020 15 Harvey RA, Rassen JA, Kabelac CA. et al. Real-world data suggest antibody positivity to SARS-CoV-2 is associated with a decreased risk of future infection. medRxiv. Cold Spring Harbor Laboratory; 2020 16 Mustapha JO, Abdullahi IN, Ajagbe OOR. et al. . Heliyon 2021; 7 (01) e05951 17 Zou L, Ruan F, Huang M. et al. SARS-CoV-2 Viral load in upper respiratory specimens of infected patients. N Engl J Med 2020; 382: 1177-1179 18 Yang X, Yu Y, Xu J. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020; 8 (05) 475-481 19 Wang D, Hu B, Hu C. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323: 1061 20 Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497-506 21 Guan W, Ni Z, Hu Y. et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382 (18) 1708-1720 22 Zhou F, Yu T, Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054-1062 23 Wu Z, McGoogan J. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323 (13) 1239-1242 24 Gattinoni L, Chiumello D, Caironi P. et al. COVID-19 pneumonia: different respiratory treatments for different phenotypes?. Intensive Care Med 2020; 46 (06) 1099-1102 25 Brochard L, Slutsky A, Pesenti A. Mechanical Ventilation to Minimize Progression of Lung Injury in Acute Respiratory Failure. Am J Respir Crit Care Med 2017; 195 (04) 438-442 26 Pfeifer M, Ewig S, Voshaar T. et al. Positionspapier zur praktischen Umsetzung der apparativen Differenzialtherapie der akuten respiratorischen Insuffizienz bei COVID-19: Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin e. V. (DGP). Pneumologie 2020; 74 (06) 337-357 27 Wu C, Chen X, Cai Y. et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020; 180 (07) 934-943 28 Mehta P, McAuley DF, Brown M. et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395: 1033-1034 29 Chen N, Zhou M, Dong X. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395: 507-513 30 Kluge S, Janssens U, Welte T. et al. S2k-Leitlinie – Empfehlungen zur stationären Therapie von Patienten mit COVID-19. Pneumologie 2021; 75 (02) 88-112 31 Gross O, Moerer O, Weber M. et al. COVID-19-associated nephritis: early warning for disease severity and complications?. Lancet 2020; 395(10236): e87-e88 32 Reusken CBEM, Broberg EK, Haagmans B. et al. Laboratory readiness and response for novel coronavirus (2019-nCoV) in expert laboratories in 30 EU/EEA countries, January 2020. Eurosurveillance 2020; 25 (06) 2000082 33 Robert Koch-Institut – RKI. Coronavirus SARS-CoV-2 – Hinweise zur Testung von Patienten auf Infektion mit dem neuartigen Coronavirus SARS-CoV-2. Im Internet: http://bit.ly/34c-8DiX 34 Robert Koch-Institut – RKI. Coronavirus SARS-CoV-2 – Optionen zum Management von Kontaktpersonen unter medizinischem Personal bei Personalmangel. Im Internet (Stand: 23.01.2021): http://bit.ly/2NrugGo 35 Anonymous COVID-19: protecting health-care workers. Lancet 2020; 395: 922 36 AWMF online. Empfehlungen Krankenhaushygiene: Hygieneanforderungen bei ausgewählten respiratorisch übertragbaren Infektions-Erkrankungen (aerogen und Tröpfchen); 31.01.2016. Im Internet: http://bit.ly/3u3CcOX 37 Robert Koch-Institut – RKI. Infektionsprävention im Rahmen der Pflege und Behandlung von Patienten mit übertragbaren Krankheiten. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 2015; 58: 1151->1170 38 Smith JD, MacDougall CC, Johnstone J. et al. Effectiveness of N95 respirators versus surgical masks in protecting health care workers from acute respiratory infection: a systematic review and meta-analysis. CMAJ 2016; 188 (08) 567-574 39 Radonovich LJ, Simberkoff MS, Bessesen MT. et al. N95 Respirators vs. Medical Masks for Preventing Influenza Among Health Care Personnel. JAMA 2019; 322: 824 40 Sektion 2 Endoskopie der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin. Empfehlung. Im Internet: http://bit.ly/3a1Qt5B 41 Fan E, Brodie D, Slutsky AS. Acuterespiratorydistresssyndrome. JAMA 2018; 319: 698 42 Alhazzani W, Evans L, Alshamsi F. et al. Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update. Crit Care Med 2021; online ahead of print 43 Wichmann D, Sperhake JP, Lütgehetmann M. et al. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study. Ann Intern Med 2020; 173: 268-277 44 LeTourneau JL, Pinney J, Phillips CR. Extravascular lung water predicts progression to acute lung injury in patients with increased risk. Crit Care Med 2012; 40: 847-854 45 Bein B, Renner J. Best practice & research clinical anaesthesiology: Advances in haemodynamic monitoring for the perioperative patient. Best Pract Res Clin Anaesthesiol 2019; 33: 139-153 46 Müller C. DAZ online. WHO rät doch nicht von Ibuprofen ab: Ibuprofen und COVID-19: WHO rudert zurück. Im Internet: http://bit.ly/3qQPbkA 47 Cao B, Wang Y, Wen D. et al. A Trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020; 382 (19) 1787-1799 48 Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A systematic review. J Med Virol 2020; 92: 479-490 49 Sheahan TP, Sims AC, Leist SR. et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020; 11 (01) 222 50 Beigel JH, Tomashek KM, Dodd LE. et al. Remdesivir for the Treatment of Covid-19 – Final Report. N Engl J Med 2020; 383: 1813-1826 51 WHO Solidarity Trial Consortium. Pan H, Peto R. et al. Repurposed Antiviral Drugs for Covid-19 – Interim WHO Solidarity Trial Results. N Engl J Med 2021; 384 (06) 497-511 52 Siemieniuk R, Rochwerg B, Agoritsas T. et al. A living WHO guideline on drugs for covid-19. BMJ 2020; 370: m3379 53 Touret F, de Lamballerie X. Of chloroquine and COVID-19. Antiviral Res 2020; 177: 104762 54 Gottlieb RL, Nirula A, Chen P. et al. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19. JAMA 2021 Jan 21. Im Internet: http://bit.ly/3cjlO6I 55 Weinreich DM, Sivapalasingam S, Norton T. et al. REGNCOV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N Engl J Med 2021; 384 (03) 238-251 56 Group TRC. Dexamethasone in Hospitalized Patients with Covid-19 – Preliminary Report. N Engl J Med 2020 July 17. Im Internet: http://bit.ly/3psFhFt 57 Robert Koch-Institut – RKI. Coronavirus SARS-CoV-2 – Therapieübersicht bei COVID-19. Im Internet: http://bit.ly/3pli8E5 58 Ramanathan K, Antognini D, Combes A. et al. Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases. Lancet Respir Med 2020; 8 (05) 518-526 59 Peek GJ, Mugford M, Tiruvoipati R. et al. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet 2009; 374: 1351-1363 60 Combes A, Hajage D, Capellier G. et al. Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome. N Engl J Med 2018; 378: 1965-1975 61 Shekar K, Badulak J, Peek G. et al. Extracorporeal Life Support Organization Coronavirus Disease 2019 Interim Guidelines: A Consensus Document from an International Group of Interdisciplinary Extracorporeal Membrane Oxygenation Providers. ASAIO J 2020; 66: 707-721 62 Barbaro RP, MacLaren G, Boonstra PS. et al. Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry. Lancet 2020; 396(10257): 1071-1078 63 S3-Leitlinie Invasive Beatmung und Einsatz extrakorporaler Verfahren bei akuter respiratorischer Insuffizienz. 1. Aufl. Langversion, Stand: 04.12.2017. Im Internet: http://bit.ly/2YWLcaK 64 Ruan Q, Yang K, Wang W. et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020; 46 (05) 846-848 65 Kogelmann K, Jarczak D, Scheller M. et al. Hemoadsorption by CytoSorb in septic patients: a case series. Crit Care 2017; 21: 74 66 Olson SW, Oliver JD, Collen J. et al. Treatment for Severe Coronavirus Disease 2019 With the Seraph-100 Microbind Affinity Blood Filter. Crit Care Explor 2020; 2 (08) e0180
